Neurotoxicity associated with acyclovir in end stage renal failure.
OBJECTIVE
To alert practitioners to the danger of acyclovir neurotoxicity occurring in the presence of renal failure.


METHODS
Two case reports of acyclovir neurotoxicity in the patients on continuous ambulatory peritoneal dialysis.


RESULTS
In one case neurotoxicity resulted from the use of a dosage regimen that would be appropriate in patients with normal renal function. In the other case, neurotoxicity occurred even though a reduced dose of acyclovir was given. Supportive management resulted in a complete recovery.


CONCLUSIONS
In patients with end stage renal failure with varicella zoster infections, when acyclovir is prescribed the loading dose should be 400 mg and the maintenance dose should be 200 mg twice daily.
Kitching
A R
AR
Department of Medicine, Wellington School of Medicine.
Fagg
D
D
Hay
N M
NM
Hatfield
P J
PJ
Macdonald
A
A
D000212:Acyclovir / Q000008:administration & dosage / Q000009:adverse effects*; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006562:Herpes Zoster / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000628:therapy; D008875:Middle Aged; D009420:Nervous System / Q000187:drug effects*; D010531:Peritoneal Dialysis, Continuous Ambulatory
D000998:Antiviral Agents; D000212:Acyclovir